Request Trial
shutterstock_1395147236_poptika
Poptika / Shutterstock.com
15 December 2020Big PharmaSally Shorthose and Rumana Khanom

What 2020 means for the life sciences

2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sandoz strikes fresh biosimilar deal with South Korean biotech
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
INTA: ‘New normal’ for in-house counsel as budgets fall
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.


Editor's picks

Masimo convinces judge that Apple took secrets—but it’s not enough
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026

Editor's picks

Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026

More features

Masimo convinces judge that Apple took secrets—but it’s not enough
Sandoz strikes fresh biosimilar deal with South Korean biotech
US firm boosts patent bench with Desmarais hire
HSF Kramer hires patent litigator as partner in Germany
INTA: ‘New normal’ for in-house counsel as budgets fall
Mylan withdraws defence claims against Novo in Wegovy dispute
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Astellas blocks generic version of key urology drug until 2030